Sanofi's multiple myeloma drug Sarclisa has become the first cancer treatment in the EU approved for administration via a palm-sized on-body injector, enabling at-home chemotherapy. This regulatory milestone signals a shift toward portable drug delivery systems that could influence how injectable therapies are packaged, distributed, and administered outside hospital settings—a trend relevant for medical aesthetics distributors and clinic buyers exploring home-use or portable device partnerships.
Regulatory milestone
On 8 June 2026, Sanofi announced that the European Union approved Sarclisa (isatuximab) for delivery via a portable on-body injector and manual subcutaneous injection. This makes Sarclisa the first cancer drug in the EU to be administered through such a device. The approval allows for flexible use, including in the patient's home environment, reducing the need for hospital stays for chemotherapy infusions.
Device and delivery details
The on-body injector is a palm-sized device that delivers the drug under the skin at the push of a button. The injection time for both the device and manual subcutaneous injection is 13 minutes. This technology could be adapted for other injectable therapies, including those in medical aesthetics, where patient convenience and at-home use are growing priorities.
Global regulatory review
Sarclisa has been approved for treatment in nearly 60 countries since 2020. The new delivery method is currently under review by regulators in the United States, Japan, and China. Approval in these markets could expand the supply chain for portable injectors and subcutaneous formulations, creating opportunities for OEMs and distributors of drug-device combination products.
What buyers should watch
Distributors and clinic buyers should monitor regulatory decisions in the US, Japan, and China for Sarclisa's at-home injectable format. The success of this delivery system may accelerate demand for portable injectors and subcutaneous formulations in oncology and potentially in medical aesthetics. Partnerships with device manufacturers and contract development organizations could become strategic for companies seeking to offer home-use injectable solutions.
Source: Read the original report | Published: June 08, 2026